| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 257,5 k € | |||||||||||||||
| Gross margin | 640,2 k € | +11.1% | 576,0 k € | +7.8% | 534,3 k € | -13.9% | 620,3 k € | -19.8% | 773,5 k € | +41.8% | 545,6 k € | +84.6% | 295,5 k € | -20.3% | 370,8 k € | +57.5% | 235,4 k € | -38.1% | 380,4 k € | +19.2% | 319,1 k € | +29.2% | 246,9 k € | +38.9% | 177,8 k € | -5.9% | 189,0 k € | +20.5% | 156,9 k € | |
| EBITDA | 636,9 k € | +11.2% | 573,0 k € | +7.8% | 531,8 k € | -13.9% | 617,6 k € | -19.9% | 770,9 k € | +42.0% | 543,0 k € | +47.9% | 367,1 k € | +26.0% | 291,4 k € | +25.1% | 232,9 k € | -38.4% | 377,9 k € | +19.3% | 316,6 k € | +29.3% | 244,8 k € | +38.8% | 176,3 k € | -5.8% | 187,1 k € | +20.7% | 155,0 k € | |
| Operating profit | 542,1 k € | +1.2% | 535,7 k € | +8.3% | 494,5 k € | -14.3% | 577,4 k € | -21.1% | 731,6 k € | +45.7% | 502,1 k € | +53.6% | 327,0 k € | +29.4% | 252,6 k € | +38.1% | 182,9 k € | -42.0% | 315,1 k € | +27.8% | 246,5 k € | +36.7% | 180,3 k € | +35.9% | 132,7 k € | -2.1% | 135,6 k € | +56.2% | 86,8 k € | |
| Profit/loss | 386,5 k € | +0.1% | 386,1 k € | +8.0% | 357,5 k € | -10.4% | 398,8 k € | -25.8% | 537,6 k € | +51.9% | 353,9 k € | +98.9% | 178,0 k € | +18.0% | 150,8 k € | +36.7% | 110,3 k € | -44.5% | 198,6 k € | +87.1% | 106,2 k € | +24.9% | 85,0 k € | -9.7% | 94,1 k € | -3.1% | 97,2 k € | +90.2% | 51,1 k € | |
| Equity | 3,4 M € | +12.8% | 3,0 M € | +14.7% | 2,6 M € | +10.9% | 2,4 M € | +20.2% | 2,0 M € | +37.5% | 1,4 M € | +32.8% | 1,1 M € | +19.8% | 900,9 k € | +20.1% | 750,1 k € | +17.2% | 639,7 k € | +45.0% | 441,1 k € | +31.7% | 334,9 k € | +34.0% | 249,9 k € | +55.5% | 160,7 k € | +153.0% | 63,5 k € | |
| Total assets | 3,6 M € | +15.7% | 3,1 M € | +12.6% | 2,8 M € | +8.5% | 2,6 M € | +15.9% | 2,2 M € | +31.9% | 1,7 M € | +30.5% | 1,3 M € | -0.5% | 1,3 M € | +17.1% | 1,1 M € | +7.0% | 1,0 M € | +16.3% | 888,4 k € | +11.8% | 794,9 k € | +16.8% | 680,4 k € | +4.8% | 649,3 k € | +57.7% | 411,8 k € | |
| Cash | 692,5 k € | -28.9% | 974,0 k € | +10.7% | 879,8 k € | -20.8% | 1,1 M € | +15.1% | 964,8 k € | +101.9% | 477,8 k € | +86.7% | 255,9 k € | -30.3% | 367,5 k € | +101.1% | 182,7 k € | -8.7% | 200,1 k € | -5.1% | 210,7 k € | -6.9% | 226,4 k € | +6.1% | 213,3 k € | +45.1% | 147,0 k € | +13.5% | 129,5 k € | |
| Debts | 232,6 k € | +85.3% | 125,6 k € | -21.6% | 160,2 k € | -19.9% | 200,0 k € | -19.1% | 247,1 k € | -0.3% | 247,8 k € | +18.5% | 209,1 k € | -34.3% | 318,4 k € | +8.1% | 294,5 k € | -8.3% | 321,1 k € | -12.2% | 365,8 k € | -20.0% | 457,6 k € | +6.9% | 428,2 k € | -11.8% | 485,7 k € | +39.9% | 347,3 k € | |
Private limited company · Roeselare · incorporated on 30/03/2010
Private limited company profitable and well capitalised. Cash position declining (-28.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Hilde Vanpoucke - Apotheker Klinisch Bioloog is a Private limited company incorporated in 2010. Its main activity is: Other human health activities. Its registered office is in Roeselare.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette